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Background: The purpose of this study was to determine whether the use of
low-molecular-weight heparin before coronary artery bypass surgery would be
associated with an increase in bleeding and use of blood products after the operation.
Methods: Sixty-four patients (48 men and 16 women) aged 64 10 years who were
undergoing primary coronary artery bypass surgery were prospectively studied.
Forty-one patients were treated with either subcutaneous enoxaparin 1 mg/kg twice
daily (n  21; enoxaparin group) or intravenous heparin (n  20; heparin group).
Patients received the last dose of enoxaparin 8.7  0.75 hours (range, 8-10 hours)
before skin incision. Heparin was stopped before transfer to the operating room. An
additional 23 consecutive patients who received neither enoxaparin nor heparin
served as controls (n  23). Anti–factor Xa activity, a measure of enoxaparin and
heparin activity, was measured at the start of the operation in all patients.
Results: There was no perioperative mortality. The length of stay and frequency of
postoperative complications were similar between groups. Preoperative anti–factor
Xa activity was present only in the enoxaparin group (0.43  0.25 IU/mL). Chest
tube drainage at 24 hours was 553  160 mL, 532  140 mL, and 587  230 mL
for the enoxaparin, heparin, and control groups, respectively (P  .48). There was
no difference among groups in the amount of blood products transfused.
Conclusions: Enoxaparin administration more than 8 hours before coronary artery
bypass surgery is not associated with increased postoperative bleeding or blood
product transfusion.
Low-molecular-weight heparins (LMWH) are considered to be amainstay of therapy for patients with acute coronary syndromes.1LMWH are fragments of unfractionated heparin that exert theiranticoagulant activity by activating antithrombin. The activated an-tithrombin accelerates its interaction with thrombin and activatedfactor Xa. Unlike unfractionated heparin, which has equivalent ac-
tivity against factor Xa and thrombin, LMWH have greater activity against factor
Xa.2 LMWH produce a more predictable anticoagulant response than unfractionated
heparin.3 Consequently, in contrast to patients treated with unfractionated heparin,
laboratory monitoring is usually unnecessary for patients treated with LMWH.2 In
addition to the better bioavailability and ease of use of LMWH, enoxaparin, an
LMWH, has been shown to be superior to unfractionated heparin in the treatment of
acute coronary syndrome.4-6 Therefore, patients with more urgent conditions who
are waiting for coronary artery bypass graft surgery (CABG) may be treated with
LMWH before surgery. Because the LMWH duration of activity is longer than that
of unfractionated heparin and is only partially neutralized by protamine sulfate,2,7
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we wanted to find out whether the use of LMWH before
CABG is associated with an increase in postoperative bleed-
ing and use of blood products.
Patients and Methods
The study was approved by the hospital ethics committee, and
written, informed consent was obtained from all patients. Sixty-
four patients undergoing primary CABG were prospectively stud-
ied. Forty-one patients with urgent conditions were treated with
either subcutaneous enoxaparin 1 mg/kg twice daily (n  21;
enoxaparin group) or intravenous unfractionated heparin (n  20;
heparin group). Patients received the last dose of enoxaparin at
midnight before their operation if they received their operation in
a morning session or at 7:00 AM if they underwent operation in an
afternoon session. The average time between the last enoxaparin
injection and operation was 8.7  0.75 hours (range, 8-10 hours)
before skin incision. Unfractionated heparin was discontinued
before transfer to the operating room. Patients were assigned to
enoxaparin or heparin groups according to the primary physician
preference. Twenty-three consecutive elective patients who re-
ceived neither LMWH nor unfractionated heparin served as a
control group. Anti–factor Xa activity, a measure of LMWH and
unfractionated heparin activity, was measured at the start of the
operation (skin incision) in all patients by a chromogenic assay
(Berichrom Heparin; Dade Behring Marburg GmbH, Marburg,
Germany).
All patients received aspirin until the day of the operation. The
operation was performed via a median sternotomy in a standard
fashion for all patients. The left internal thoracic artery was used
in all cases and harvested first, followed by the right internal
thoracic artery, when used. The left radial artery was harvested
simultaneously with the saphenous vein, when needed. Cardiopul-
monary bypass was achieved with aortic and single venous can-
nulae. The patients were uniformly cooled to 32°C. Cardioplegia
was achieved with antegrade and retrograde cold blood cardiople-
gia with repeated doses every 20 minutes. All distal anastomoses
were performed first, and proximal anastomoses were performed
during the same crossclamp while the heart was perfused retro-
gradely with warm blood. The mediastinal and left chest were
routinely drained, and the right chest was drained only when the
right pleura was opened. The activated clotting time values were
kept between 500 and 600 seconds during the bypass period.
Continuous variables are expressed as mean  SD. Noncon-
tinuous data are expressed as number of events and percentage. For
statistical analysis, 1-way analysis of variance was used for nor-
mally distributed continuous variables, the Kruskal-Wallis non-
parametric test for abnormally distributed variables, and the 2 test
for categorical variables. Linear regression analysis was used to
search for associations between anti–factor Xa activity and post-
operative bleeding. To calculate the necessary sample size for the
study, a power analysis for analysis of variance was performed.
We defined a difference of at least 200 mL of chest tube drainage
between groups with a pooled SD of 230 mL to be of clinical
importance. To achieve an 80% power to detect such a difference
with an  of .05, 20 patients were calculated to be required for
each group.
Results
Preoperative and operative data are presented in Table 1.
More patients in the enoxaparin and heparin groups had
TABLE 1. Preoperative and operative characteristics
Variable
Enoxaparin
(n  21)
Heparin
(n  20)
Control
(n  23)
P
value
Age (y) 66.5 8.3 64 12 63 11 .58
BSA (m2) 1.8 0.14 1.85 0.14 1.8 0.2 .74
Female sex 5 (24) 5 (25) 6 (26) .99
Diabetes mellitus 13 (62) 11 (55) 10 (43) .3
Hypertension 12 (57) 13 (65) 14 (61) .89
Current smoker 8 (38) 6 (30) 6 (26) .56
COPD 1 (5) 1 (5) 0 .54
History of CVA 1 (5) 2 (10) 0 .3
Creatinine 2 mg/100 mL 1 (5) 1 (5) 1 (4) .99
History of MI 12 (57) 9 (45) 10 (44) .6
Unstable angina 18 (86) 15 (75) 1 (4) .001
LVEF (%) 54 12 50 11 54 10 .46
Left main disease 3 (14) 7 (35) 5 (18) .29
Triple vessel disease 13 (62) 11 (55) 14 (61) .96
Preoperative IABP 0 6 (30) 0 .001
No. of grafts 3 1 2.7 1 3 1 .65
Double thoracic 4 (19) 2 (10) 6 (26) .4
CPBt (min) 116 31 113 38 122 40 .7
XCt (min) 81 23 82 29 87 24 .73
Heparin (mg/kg) 5.4 0.54 5.6 0.66 5.3 0.95 .38
Protamine (mg/kg) 4 0.6 4.3 0.6 4.4 1 .25
Data are presented as mean SD for continuous variables and as number of occurrences (%) for noncontinuous variables. BSA, Body surface area; COPD,
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; MI, myocardial infarction; LVEF, left ventricular ejection fraction; IABP, intra-aortic
balloon pump; CPBt, cardiopulmonary bypass time; XCt, crossclamp time.
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unstable angina compared with the control group. An intra-
aortic balloon pump was present before surgery in 6 pa-
tients, all in the heparin group. No differences were ob-
served with regard to type of graft used, number of grafts
per patient, cardiopulmonary bypass, and crossclamp time.
There was no difference among groups in preoperative
laboratory values reflecting liver or kidney function. There
was no perioperative mortality, and the length of stay and
frequency of postoperative complications were similar
among groups (Table 2). Although a postoperative increase
in serum creatinine was common, renal failure (defined as
serum creatinine 2 mg/100 mL) was present only in those
patients who had preoperative serum creatinine 2 mg/100
mL. Only 1 patient, in the heparin group, required tempo-
rary hemodialysis. Four patients had postoperative infection
that required administration of antibiotics.
Preoperative and postoperative coagulation profiles and
hemoglobin were similar among groups, except for preop-
erative heparin activity (anti–factor Xa activity), which was
documented only in the enoxaparin group (Table 3). There
was no significant difference among the groups in the
amount of mediastinal bleeding during the first 24 hours
after the operation or in the amount of blood products
transfused during the hospital stay (Table 4). Moreover, a
linear regression analysis demonstrated no correlation be-
tween preoperative anti–factor Xa activity and 24-hour
postoperative bleeding (r  0.16; P  .22).
Discussion
In the current era of cardiology, in which several potent
antithrombotic and antiplatelet agents are used for a variety
of indications, cardiac surgeons are faced with an increasing
number of patients who are referred to operation while
being treated with one or more of those agents. Because
patients may bleed after cardiac surgery, a decision has to be
made regarding the proper timing of the operation. Enox-
aparin, an LMWH, is commonly used in cardiac patients. It
has a longer duration of action than unfractionated heparin
and is only partially neutralized by protamine sulfate.2,7
Therefore, a bleeding tendency after CABG may be antic-
ipated. In this study, we asked whether enoxaparin given
before urgent CABG was associated with an increased
tendency for postoperative bleeding or blood product trans-
fusion. We showed that if the last dose of enoxaparin was
given 8.7 0.75 hours before operation, then the blood loss
and blood products transfused were similar between those
who received enoxaparin and those who did not. Jones and
colleagues8 retrospectively studied 1159 patients who re-
ceived either unfractionated heparin or enoxaparin within
48 hours of CABG, and they found higher incidence of
re-exploration for bleeding after enoxaparin administration.
They could not show any difference in the amount of blood
loss or blood products transfused between those who re-
ceived enoxaparin and those who received unfractionated
heparin.8 Of concern is the lack of correlation between the
increased reexploration rate and bleeding or blood products
transfused. In addition, there is no temporal relationship
between the last dose of enoxaparin administration and
postoperative bleeding or likelihood of re-exploration. It
may well be that those who were re-explored received the
last enoxaparin dose shortly before the operation. In con-
trast, Clark and associates,9 who performed a prospective
study on 390 patients and investigated the influence of
dalteparin, a different type of LMWH, on postoperative
bleeding after cardiac surgery, did not find an increase in the
re-exploration rate but found that patients who received
dalteparin less than 12 hours before operation had an in-
crease in blood loss and blood transfusion. Skubas and
associates10 described a patient who bled 2360 mL during
the first 24 hours after CABG. This patient received enox-
aparin on the day of operation and also received tirofiban, a
short-acting IIb/IIIa platelet glycoprotein receptor inhibitor,
which was discontinued the night before operation. In all of
these studies, anti–factor Xa activity was not measured, so
a reliable measure of heparin activity at the start of the
operation is lacking. The sporadic use of LMWH as an
anticoagulant during cardiopulmonary bypass has been
shown to be associated with increased postoperative bleed-
ing.11,12 It may well be that the patients who bled or were
re-explored in these studies8-10 had high anti–factor Xa
activity during the operation and, as a result, had a higher
tendency to bleed or to be re-explored.
In this study, preoperative heparin activity, measured by
anti–factor Xa activity, was documented only in the group
of patients who received enoxaparin. Patients who received
unfractionated heparin did not show anti–factor Xa activity
and had activated partial thromboplastin times within nor-
mal range at the start of the operation. Whether this finding
reflects the short half-life of this product—so that by the
time the patient arrived at the operating room it was elim-
inated from the blood—or whether the patients were not
properly treated with unfractionated heparin before the op-
eration is not known.
TABLE 2. Length of stay and postoperative complications
Variable
Enoxaparin
(n  21)
Heparin
(n  20)
Control
(n  23) P value
Length of stay (d) 6.7 4 7.1 5 6.7 4.2 .95
Perioperative MI 0 0 0
CVA 0 0 0
Cr 2 mg/100 mL 1 (5) 1 (5) 1 (4) .99
Dialysis 0 1 (5) 0 .3
Infection 1 (5) 1 (5) 2 (9) .83
Data are presented as mean SD for continuous variables and as number
of occurrences (%) for noncontinuous variables. MI, Myocardial infarction;
CVA, cerebrovascular accident; Cr, plasma creatinine.
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Peak anti–factor Xa activity after subcutaneous LMWH
administration occurs within 3 to 4 hours, and the anti–
factor Xa levels are approximately 50% of peak levels 12
hours later.13 The mean anti–factor Xa activity at the start of
the operation in this study was 0.43  0.25 IU/mL for the
patients who received enoxaparin. Although enoxaparin ac-
tivity is still present, the level of activity only approaches
the therapeutic range of 0.5 to 1.1 IU/mL.14 The subthera-
peutic levels of anti–factor Xa activity found 8.7  0.75
hours after the last dose of enoxaparin may explain why
patients in this study did not show an increased tendency of
bleeding in the enoxaparin group.
Usually enoxaparin is administered twice daily. Because
most patients treated with enoxaparin do not need to pro-
ceed directly to operation on an emergency basis, there
should be no need to modify the timing of the operation or
to prematurely discontinue enoxaparin.
Heparin resistance requiring the administration of anti–
thrombin III or fresh frozen plasma during cardiopulmonary
bypass to achieve appropriate activated clotting time was
not documented in this study. In the literature it was iden-
tified in up to 26% of patients undergoing cardiac surgery
and was shown to be associated with preoperative use of
unfractionated heparin.15 No data are available regarding
heparin resistance and preoperative use of LMWH. The
absence of heparin resistance with preoperative use of enox-
aparin in this study may imply that it is not more prevalent
than the resistance experienced after preoperative use of
unfractionated heparin. However, a larger study designed to
answer this question is required to make such a conclusion.
Although this is a prospective study, it was not blinded,
and the decision about whether a patient would receive
enoxaparin or unfractionated heparin was the primary phy-
sician’s decision according to his or her preference. The
patient population was not homogeneous among groups,
and the sample size in this study was small. Nevertheless,
because the differences among groups in chest tube drain-
age were not statistically different or of any clinical impor-
tance (defined as chest tube drainage of more than 200 mL
for 24 hours), the results seem valid. Enoxaparin was ad-
ministered 8 to 10 hours before operation, and no conclu-
sion or recommendation can be made if the interval between
the last enoxaparin dose and operation is less than 8 hours.
Larger prospective studies need to be performed to clarify
the contrasting data regarding the re-exploration rate after
LMWH administration before CABG. Until such studies are
TABLE 3. Preoperative and postoperative hemoglobin and coagulation profile
Variable
Enoxaparin
(n  21)
Heparin
(n  20)
Control
(n  23) P value
Before surgery
Hb (mg/100 mL) 11.2 1.3 11.4 1.4 11.4 1.5 .86
Platelets ( 103/mL) 208 49 225 59 194 50 .18
INR 1.1 0.08 1.1 0.07 1.1 0.07 .43
aPTT (s) 32 7 31 6 29 4 .39
Anti–factor Xa (IU/mL) 0.43 0.25 0.09 0.07 0.05 0.07 .001
24 h after surgery
Hb (mg/100 mL) 10 0.9 10.4 1 10.2 0.9 .3
Platelets ( 103/mL) 149 55 161 58 136 55 .36
INR 1.2 0.12 1.2 0.2 1.2 0.11 .71
aPTT (s) 29 2.8 30 5.4 29 3.3 .79
At discharge
Hb (mg/100 mL) 10.8 0.6 11 0.7 10.5 1 .4
Data are presented as mean  SD. Hb, Hemoglobin; INR, international normalized ratio; aPTT, activated partial thromboplastin time.
TABLE 4. Blood loss and blood products transfused
Variable
Enoxaparin
(n  21)
Heparin
(n  20)
Control
(n  23) P value
24-h bleeding (mL) 553 160 532 140 587 230 .48
PRBC (U)* 1 (0–3) 1 (0–2) 1 (0–3) .65
FFP (U)* 0 (0–2) 0 (0–2) 0 (0–2) .83
Platelets (U)* 0 (0–6) 0 0 (0–6) .25
No. transfused* 13 (62) 12 (60) 16 (70) .82
Data are presented as mean  SD for bleeding, as number of occurrences (%) for number transfused, and as median (range) for PRBC, FFP, and platelets.
PRBC, Packed red blood cells; FFP, fresh frozen plasma.
*During hospital stay.
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available, clinicians may consider discontinuing the use of
these agents and initiating the use of unfractionated heparin
at least 24 to 48 hours before operation.
In conclusion, in this small series of patients at low risk
for postoperative bleeding, enoxaparin administration more
than 8 hours before CABG proved not to be associated with
increased postoperative bleeding or blood product transfu-
sion.
We thank Nurit Ben-Yosef, MSc, who carefully analyzed the
anti–factor Xa activity assay.
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